RxDoctor Payments Data

Heather Mosley, APRN

Adult Health · Lincoln, NENPI 1376977876

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,276 of the $5,934 with a category attached, or 72.1%. 19 manufacturers reported payments, led by Abbott at 51.7% of the total. Among adult health clinicians in NE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$5,934in general payments, 2019–2025

Across 153 payments — averaging $38.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$3K
  • Impulse Dynamics (USA) Inc.$856
  • AstraZeneca$454
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$282
  • Scpharmaceuticals Inc.$191
  • Bayer$178
  • plus $904 from 13 others

What the payments were for

  • Travel & lodging$1,65828%
  • Food & beverage$4,27672%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,934 in reported general payments places this provider in the 95th percentile of 58 adult health providers in Nebraska.

See all adult health providers in Nebraska

Medicare billing

Part B allowed, 2024
$95,474
Medicare patients
484
Services billed
1,318

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan614$570,357
JardianceEmpagliflozin439$371,055
EliquisApixaban384$331,185
FarxigaDapagliflozin Propanediol378$296,544
XareltoRivaroxaban220$208,908
Torsemide806$23,778
Metoprolol Succinate1,006$15,339
Potassium Chloride542$15,239
Repatha SureclickEvolocumab13$13,546
Ranolazine ErRanolazine53$5,963
Dabigatran EtexilateDabigatran Etexilate Mesylate18$5,743
Atorvastatin Calcium482$4,834
Nebivolol Hcl63$4,227
Furosemide750$4,008
Spironolactone554$3,337

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$110$570,357614 claims
Boehringer IngelheimJardiance$125$371,055439 claims
PfizerEliquis$71$331,185384 claims
AstraZenecaFarxiga$454$296,544378 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 adult health providers in Nebraska.

Other adult health in Lincoln

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →